Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients

被引：26
|
作者：
Taniyama, M
Ohbayashi, S
Narita, M
Nakazawa, R
Hasegawa, S
Azuma, N
Teraoka, S
Ota, K
Yamauchi, S
Margolin, SB
机构：
[1] NARITA MEM HOSP, DEPT INTERNAL MED, TOYOHASHI, AICHI 441, JAPAN
[2] TOKATSU CLIN HOSP, DEPT NEPHROL, MATSUDO, CHIBA 271, JAPAN
[3] TOKYO WOMENS MED COLL, DEPT SURG, KIDNEY CTR, SHINJUKU KU, TOKYO 162, JAPAN
[4] KDL INC, CHIYODA KU, TOKYO, JAPAN
[5] MARNAC INC, DALLAS, TX 75225 USA
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1997年 / 52卷 / 01期
关键词：
pirfenidone; peritoneal sclerosis; haemodialysis;
D O I：
10.1007/s002280050252
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients
    M. Taniyama
    S. Ohbayashi
    M. Narita
    R. Nakazawa
    S. Hasegawa
    N. Azuma
    S. Teraoka
    K. Ota
    S. Yamauchi
    S. B. Margolin
    European Journal of Clinical Pharmacology, 1997, 52 : 77 - 78
  • [2] Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy chinese volunteers
    Shi, Shaojun
    Wu, Fianhong
    Chen, Huating
    Chen, Hui
    Wu, Jun
    Zeng, Fandian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (10): : 1268 - 1276
  • [3] Pharmacokinetics of antifibrotic drug pirfenidone, in mice following intravenous administration
    Giri, SN
    Wang, QJ
    Xie, Y
    Morin, D
    Lango, J
    Margolin, SB
    Buckpitt, AR
    FASEB JOURNAL, 2001, 15 (05): : A917 - A917
  • [4] Pharmacokinetics, tolerability, and safety of pirfenidone (PFD), an antifibrotic agent, following single and multiple oral doses in healthy volunteers
    Shi, Shaojun
    Wu, Jianhong
    Chen, Huating
    Chen, Hui
    Wu, Jun
    Zeng, Fandian
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 197 - 197
  • [5] Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis
    Dosanjh, AK
    Wan, B
    Throndset, W
    Sherwood, S
    Morris, RE
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) : 1910 - 1911
  • [6] Pirfenidone -: Deskar® -: Antifibrotic
    不详
    DRUGS OF THE FUTURE, 2000, 25 (06) : 645 - 646
  • [7] Pirfenidone and optimized pirfenidone analogs for antifibrotic indications
    Ramphal, John
    Pan, Lin
    Schaefer, Caralee
    Seiwert, Scott
    Buckman, Brad
    Schwarz, Jacob
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [8] Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration
    Giri, SN
    Wang, QJ
    Xie, Y
    Lango, J
    Morin, D
    Margolin, SB
    Buckpitt, AR
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2002, 23 (05) : 203 - 211
  • [9] PHARMACOKINETICS OF THE ANTIFIBROTIC DRUG PIRFENIDONE IN CHILD PUGH A AND B CIRRHOTIC PATIENTS COMPARED TO HEALTHY AGE-MATCHED CONTROLS
    Poo, J. L.
    Bernal, R.
    Aguilar, J. R.
    Alonso, R.
    Balderas, R.
    Pineyro, E.
    Gomez, M.
    Escobar, J.
    Mora, C.
    Hernandez, N.
    Magana, R.
    Pena, P.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S292 - S293
  • [10] The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice
    Takanori Yamazaki
    Naoto Yamashita
    Yasukatsu Izumi
    Yasuhiro Nakamura
    Masayuki Shiota
    Akihisa Hanatani
    Kenei Shimada
    Takashi Muro
    Hiroshi Iwao
    Minoru Yoshiyama
    Hypertension Research, 2012, 35 : 34 - 40
12345